Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression by unknown
Datto et al. Ann Gen Psychiatry  (2016) 15:9 
DOI 10.1186/s12991-016-0096-0
PRIMARY RESEARCH
Bipolar II compared with bipolar I 
disorder: baseline characteristics and treatment 
response to quetiapine in a pooled analysis 
of five placebo-controlled clinical trials of acute 
bipolar depression
Catherine Datto*, William J. Pottorf, Louisa Feeley, Scott LaPorte and Charlie Liss
Abstract 
Background: Bipolar I and II represent the most common and severe subtypes of bipolar disorder. Although bipolar 
I disorder is relatively well studied, the clinical characteristics and response to treatment of patients with bipolar II 
disorder are less well understood.
Methods: To compare the severity and burden of illness of patients with bipolar II versus bipolar I disorder, baseline 
demographic, clinical, and quality of life data were examined in 1900 patients with bipolar I and 973 patients with 
bipolar II depression, who were enrolled in five similarly designed clinical placebo-controlled trials of quetiapine 
immediate-release and quetiapine extended-release. Acute (8 weeks) response to treatment was also compared by 
assessing rating scale scores, including Montgomery–Åsberg depression rating scale, Hamilton rating scale for anxiety, 
Young mania rating scale, and clinical global impression-severity scores, in the bipolar I and II populations in the same 
pooled database.
Results: Patients with bipolar I and bipolar II depression were similar in demographics, baseline rating scale scores 
(depression, anxiety, mania, and quality of life), and mood episode histories. Symptom improvements in response to 
quetiapine were greater versus comparators (lithium, paroxetine, and placebo) at 4 and 8 weeks in both bipolar I and 
II patients. Patients with the bipolar II subtype initially showed slower responses to all treatments, but, by 8 weeks, 
attained similar symptom improvement as patients with bipolar I depression.
Conclusions: Pooled analysis of five clinical trials of quetiapine demonstrated that patients with bipolar II depres-
sion have a similar burden of illness and quality of life to patients with bipolar I. Bipolar II patients consistently showed 
a slower response to treatments than bipolar I patients, but, after 8 weeks of treatment with quetiapine, symptom 
improvements were similar between bipolar I and II disorder subtypes.
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Background
Bipolar I and II are the most commonly diagnosed and 
the most severe subtypes of bipolar disorder [1]. There 
is increasing evidence that the bipolar II subtype is at 
least as prevalent as bipolar I disorder [2] and is associ-
ated with substantial disability, comorbidity, mortality, 
and impact on quality of life, as recognized in the latest 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) [1, 3–6]. However, despite its prevalence and 
significant morbidity, the features and the treatment of 
bipolar II disorder have not been studied as extensively as 
the bipolar I subtype.
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The diagnosis of bipolar I requires the presence of 
at least one manic episode, with or without a history 
of major depressive episodes, while bipolar II disorder 
requires at least one hypomanic and one major depres-
sive episode [1]. Depressive episodes typically exceed 
manic/hypomanic episodes in duration and frequency in 
both bipolar I and II subtypes, so patients therefore pre-
sent most frequently to physicians with depressive symp-
toms [7–10].
There is little evidence that the depressive symptoms 
and severity of bipolar I and II disorder differ. As a result, 
the two subtypes can be distinguished only by a careful 
psychiatric history that includes elucidating the presence 
or history of manic or hypomanic episodes, for bipolar 
I and bipolar II, respectively. While mania and hypoma-
nia are the core features that define bipolar I and bipo-
lar II disorder, depressive episodes are more frequent, 
enduring, and disabling over the patient’s lifetime. Addi-
tionally, the frequency and duration of depressive epi-
sodes and the chronicity of illness are typically greater 
in bipolar II disorder [11]. Because of the challenges in 
correctly diagnosing hypomania, patients with bipolar II 
disorder are also at elevated risk of being misdiagnosed 
with major depressive disorder (MDD), which shares the 
same depressive symptoms [1, 12]. Hypomania occurs 
in approximately 12  % of individuals that had an initial 
diagnosis of MDD [1, 13]. Misdiagnosing bipolar depres-
sion as MDD may lead to the initiation of inappropriate 
treatment. For example, antidepressant monotherapy in 
patients with bipolar depression is associated with ele-
vated rates of mood switch to mania [14–16], while the 
use of antidepressants as adjunctive therapy to mood sta-
bilizers does not appear to be associated with increased 
efficacy in bipolar depression [17].
Relative to bipolar I disorder, there are few studies on 
the efficacy and safety of pharmacological treatments in 
bipolar II disorder. Given the greater frequency and chro-
nicity of depressive episodes in the bipolar II subtype 
than in bipolar I subtype, medications that are effective in 
the treatment of bipolar I depression may not be directly 
applicable for treating depressive episodes of bipolar II 
disorder. As a result, there are limited recommendations 
in guidelines on the treatment of bipolar II depression 
[18–20].
Quetiapine monotherapy, in immediate-release (IR) 
and extended-release (XR) formulations, is the only US 
Food and Drug Administration (FDA)-approved treat-
ment for the acute depressive episodes of both bipolar 
I and II disorders [20]. FDA approval in this indication 
was based on five placebo-controlled clinical trials that 
included patients with both bipolar I and II subtypes 
(Table 1; Fig. 1). The five trials, with similar patient inclu-
sion and severity of illness criteria, consisted of four 
8-week studies of quetiapine IR (BipOLar DEpRession 
[BOLDER] I and II; Efficacy of Monotherapy Seroquel in 
BipOLar Depression [EMBOLDEN] I and II) [21–24] and 
one 8-week study of quetiapine XR (Study 002 XR) [25].
The inclusion of both bipolar I and II patients in these 
quetiapine clinical trials provides an opportunity to com-
pare the baseline demographics, illness severity, clinical 
characteristics, and response to treatment of patients 




Retrospective pooled analyses were performed on 2873 
patients who participated in five multicenter, fixed-dose, 
double-blind, randomized, placebo-controlled stud-
ies of quetiapine IR or XR in acute depressive episodes 
of bipolar I or II disorder (Table 1). Each study enrolled 
male or female patients aged 18–65 years with a Diagnos-
tic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) diagnosis of bipolar I or II disorder, 
most recent episode major depression [26]. The diagno-
sis was confirmed by the Structured Clinical Interview 
for DSM-IV (SCID). Additional inclusion criteria in all 
studies were a Hamilton depression rating scale (HAM-
D) 17-item score ≥20, HAM-D item 1 score ≥2, and 
Young mania rating scale (YMRS) score ≤12 [27, 28]. 
Hence, based on the HAM-D scale, these study popula-
tions can be considered to have depressive episodes of at 
least moderate severity [29]. Patients were excluded from 
the studies if they were diagnosed with Axis I disorder in 
addition to bipolar disorder.
The study designs, enrollment details, ethical approv-
als, and inclusion/exclusion criteria are described in 
detail in the original publications [21–25]. Patients in all 
five trials underwent a washout period of up to 28 days 
for antipsychotic, antidepressant, and mood-stabilizing 
medications prior to baseline assessments.
More details of treatment randomization procedures, 
dose escalation, and use of permitted co-medications 
are detailed in the original papers, but, in summary, que-
tiapine (or matched placebo) was administered orally at 
bedtime at a fixed dose of 300  mg/day or 600  mg/day 
in all studies, except in the quetiapine XR study, which 
included only the 300  mg/day dose. The EMBOLDEN I 
and II trials additionally included lithium (600–1800 mg/
day) and paroxetine (20  mg/day), respectively, as active 
controls [22, 24]. The rationales for selecting these agents 
at the doses specified are provided in the original papers.
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Assessments
Demographic characteristics, baseline illness severity, 
and clinical history
Demographic and clinical assessments that were per-
formed at baseline in all trials included: gender, age, and 
body weight; rating scale assessments of illness sever-
ity; and history of recent and lifetime mood episodes. 
Rating scale assessments performed on day 1 (after 
washout of previous medications) comprised the Mont-
gomery–Åsberg Depression Rating Scale (MADRS), 
Table 1 Overview of five acute bipolar depression studies of quetiapine IR and XR
CGI-(BP)-S clinical global impression-(bipolar)-severity, CGI-(BP)-C clinical global impression-bipolar-change, HAM-D Hamilton depression rating scale, HAM-A Hamilton 
rating scale for anxiety, MADRS Montgomery–Åsberg depression rating scale, MOS-Cog Medical Outcomes Study Cognitive Scale, PSQI Pittsburgh Sleep Quality Index, 
Q-LES-Q Quality of Life Enjoyment and Satisfaction Questionnaire, SDS Sheehan Disability Scale
a Calabrese et al. [21]
b Thase et al. [23]
c Young et al. [24]
d McElroy et al. [22]
e Suppes et al. [25]





Design Treatments Efficacy measures
Quetiapine IR
 BOLDER I (5077US/0049/
NCT00060489)a
 BOLDER II (D1447C00135/
NCT00083954)b
N = 542 (BOLDER I)




Identical study design to 
EMBOLDEN I and II










 EMBOLDEN I (D1447C00001)c
 EMBOLDEN II (D1447C00134/
NCT00119652)d
N = 802 (EMBOLDEN I)




Identical study design to 
BOLDER I and II
Quetiapine 300 mg/day or 
600 mg/day
Lithium 600–1800 mg/day 
(EMBOLDEN I)












 002 XR (D144CC00002/
NCT00422214)e
N = 280 8-week (acute phase)
Double-blind, parallel-group





Fig. 1 Designs of the five acute bipolar depression studies of quetiapine IR and XR. aAt least 5 half-lives of any prior psychotropic medications
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HAM-D, YMRS, Clinical Global Impression-Bipolar-
Severity (CGI-BP-S), and Hamilton Rating Scale for anxi-
ety (HAM-A) [30–32]. Functioning and quality of life 
were assessed, respectively, by two validated scales: the 
patient-reported Sheehan Disability Scale (SDS) and the 
Quality of Life Enjoyment and Satisfaction Questionnaire 
(Q-LES-Q) [33, 34]. Not all of these rating scales were 
assessed in every study, as itemized in Table 1.
Change in rating scale scores during quetiapine treatment
Change from baseline in MADRS total score (the pri-
mary efficacy measure) and other rating scale scores 
described above was assessed at study end (week 8) 
and at weekly or other predefined study visits. The pro-
portions of patients who met criteria for response (i.e., 
MADRS score reduction ≥50 %) and remission (MADRS 
score ≤ 12) were also calculated in treatment groups ver-
sus placebo at study end.
Statistical analyses
Statistical methods utilized in the individual studies are 
described in detail in the original papers. In brief, effi-
cacy analyses were conducted employing a linear mixed 
model repeated measures (MMRM) model to analyze the 
difference between treatments in the change from base-
line to each week. Terms were included in the model for 
treatments, center, and bipolar diagnosis strata as well as 
a term for the baseline total score as a covariate. For the 
current analyses of pooled data from the five clinical tri-
als, mean and SD or SE values are provided for baseline 
data and response to treatment, with pooling of 300 and 
600  mg dose groups for quetiapine IR in the BOLDER 
and EMBOLDEN studies (both quetiapine doses were 
significantly superior to placebo in the individual stud-
ies and in pooled analyses [35]). Efficacy of treatment 
was assessed in the pooled intent-to-treat (ITT) popu-
lation (i.e., patients who received at least one dose of 
study medication and had at least one post-baseline effi-
cacy assessment), using last observation carried forward 
(LOCF) methodology. No adjustments were made for 
multiplicity.
Analyses of safety during treatment were performed on 
the pooled safety population (i.e., patients who received 
at least one dose of the study medication). Incidences of 
adverse events, weight change, and changes in plasma 




The five clinical trials of quetiapine IR or XR investi-
gated a total of 2873 randomized patients, including 1900 
(66.1  %) with bipolar I and 973 (33.9  %) with bipolar II 
disorder. The proportions of patients with bipolar II dis-
order were similar in the BOLDER and EMBOLDEN tri-
als (range 33–38 %) and were lower in the quetiapine XR 
study (19.6 %).
Demographic characteristics, baseline illness severity, 
and clinical history
Demographic characteristics in the pooled ITT popu-
lation were broadly similar between bipolar I and II 
patients (Table  2). More than half the patients in both 
bipolar I and II subgroups were female and the mean age 
was approximately 39  years in both populations. Mean 
body weight was lower in the bipolar II than bipolar I 
population (79.7 vs 83.4  kg), but there was large inter-
patient variation. Patients with bipolar I and II disorders 
had similar clinical histories for the number of recent and 
lifetime mood episodes (Fig. 2).
Mean MADRS and HAM-D scale scores at baseline 
were comparable between patients with bipolar I and 
II disorders, indicative of moderate to severe depres-
sive symptoms in both groups (Table 3). Mean HAM-A, 
YMRS, and CGI-S scores were also similar between bipo-
lar I and II patients, indicative again of similar levels of 
anxiety, mania/hypomania, and global rating of severity. 
Table 2 Demographic characteristics at baseline in bipolar 









 Male 752 (41.6) 340 (36.9) 1092 (40.0)
 Female 1057 (58.4) 582 (63.1) 1639 (60.0)
Mean age (years), mean (SD) 39.6 (11.5) 38.8 (11.9) 39.3 (11.6)
Mean body weight (kg),  
mean (SD)
83.4 (21.4) 79.7 (19.7) 82.1 (20.9)
Fig. 2 History of mood episodes in patients in bipolar I or II sub-
groups (pooled population)
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Individual item scores on the MADRS and HAM-A 
scales demonstrated similar mean impairments in the 
core symptoms of depression and anxiety in patients with 
bipolar I or II disorder (Fig. 3).
Patient-reported functioning (SDS total and item 
scores) and quality of life (Q-LES-Q total score) demon-
strated severe impact in these measures at baseline and 
similarity between the bipolar I and II subgroups (Fig. 4). 
The comparability in baseline symptom severity, patient 
functioning, and quality of life for the bipolar I and II 
subtypes is in agreement with DSM-5 and further high-
lights the severity of depressive episodes in the bipolar II 
subtype.
Change in illness severity during treatment
Patients randomized to 8-week treatment in the five 
pooled clinical trials received quetiapine (n = 1162, bipo-
lar I; n = 598, bipolar II), placebo (n = 486; 231), lithium 
(n =  87; 49), or paroxetine (n =  74; 44). Rates of study 
discontinuation in these treatment groups were quetia-
pine (43.1 %, bipolar I; 39.6 %, bipolar II), placebo (43.2 %; 
38.7 %), lithium (42.5 %; 55.1 %), and paroxetine (63.6 %; 
53.3 %, respectively).
Treatment group comparisons
Early improvement in depressive symptoms, assessed 
by MADRS score change from baseline at weeks 2 and 
4, was most rapid in the quetiapine group in both bipo-
lar I and II patients, while symptom improvement was 
slowest in bipolar II patients treated with lithium or pla-
cebo (Fig. 5; Table 4). Least squares mean (SE) MADRS 
score changes at weeks 2 and 4 in bipolar I patients were 
−11.46 (0.24) and −15.01 (0.27) in quetiapine, −8.29 
(0.87) and −11.16 (0.98) in lithium, −9.83 (0.97) and 
−12.01 (1.09) in paroxetine, and −8.65 (0.38) and −11.31 
(0.43) in placebo groups. Changes in MADRS score at 
weeks 2 and 4 in patients with bipolar II were −10.66 
(0.34) and −13.96 (0.38), −6.43 (1.15) and −10.46 (1.31), 
−11.67 (1.22) and −13.38 (1.36), and −7.52 (0.54) and 
−10.17 (0.60), respectively.
During the second 4  weeks of treatment, the patient 
groups randomized to quetiapine continued to show 
symptom improvement, but the groups treated with 
paroxetine and placebo showed the slowest symptom 
improvement. The group treated with lithium nearly 
attained the symptom improvements achieved by the 
group randomized to quetiapine (Fig. 5; Table 4).
By study end at week 8, mean MADRS total score 
change from baseline remained greatest in the quetia-
pine group in both patients with bipolar I and II (Fig. 5; 
Table  4). In patients with bipolar I, least squares mean 
(SE, p value for comparison to placebo) MADRS score 
change was −19.01 (0.30, p <  .01) in quetiapine, −17.71 
(1.03, p  <  .05) in lithium, −16.54 (1.24, NS) in parox-
etine, and −14.29 (0.48) in placebo groups. In patients 
with bipolar II, MADRS score change was −18.44 (0.41, 
p  <  .01), −17.46 (1.43, NS), −15.35 (1.50, NS), and 
−14.57 (0.65), respectively. Analyses conducted on the 
per-protocol population yielded very similar results (data 
not shown).
With respect to individual MADRS items at week 8, 
the group treated with quetiapine showed the greatest 
improvements in most items in both bipolar I and II sub-
groups (Fig. 6). Items 3 (inner tension), 5 (reduced appe-
tite), 7 (lassitude), and 9 (pessimistic thoughts) appeared 
to respond equally well in the lithium and quetiapine 
groups.
Similar to the changes in MADRS score, greatest 
improvements at week 8 in global symptom sever-
ity (assessed by CGI-S) and anxiety (HAM-A) were 
observed in the quetiapine and lithium groups, followed 
by paroxetine and placebo (Figs.  7, 8). In patients with 
bipolar I, least squares mean (SE) CGI-S score change 
was –1.95 (0.04) in quetiapine, −1.91 (0.14) in lithium, 
Table 3 Symptom severity at  baseline in  bipolar I and  II 
subgroups (ITT population)
Rating scale ranges: CGI-S: total score range 0–7; HAM-A: total score range 0–56; 
HAM-D: total score range 0–52; MADRS: total score range 0–60; YMRS: total score 
range 0–60. For all rating scales, a high score represents greater severity
CGI-S clinical global impression-severity, HAM-A Hamilton rating scale for 
anxiety, HAM-D Hamilton depression rating scale, 17 item, ITT intent-to-treat, 
MADRS Montgomery–Åsberg depression rating scale, YMRS Young Mania rating 
scale
a HAM-A was not measured in Suppes et al. [25]
Symptom rating scale Bipolar I Bipolar II Total
Depression
MADRS
 n 1809 922 2731
 Mean (SD) 29.4 (6.2) 27.8 (6.7) 28.8 (6.4)
HAM-D
 n 1809 922 2731
 Mean (SD) 24.5 (3.4) 24.1 (3.2) 24.4 (3.4)
Anxiety
HAM-Aa
 n 1591 868 2459
 Mean (SD) 18.3 (6.3) 19.0 (6.2) 18.5 (6.3)
Mania/hypomania
YMRS
 n 1809 922 2731
 Mean (SD) 5.2 (3.1) 4.7 (2.9) 5.1 (3.1)
Global severity of illness
CGI-S
 n 1808 922 2730
 Mean (SD) 4.4 (0.7) 4.3 (0.7) 4.4 (0.7)
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−1.57 (0.18) in paroxetine, and −1.38 (0.07) in placebo 
groups. In bipolar II patients, CGI-S score change was 
−1.84 (0.06), −1.75 (0.20), −1.62 (0.21), and −1.50 (0.09), 
respectively. For HAM-A score in bipolar I patients, least 
squares mean (SE) change was −11.11 (0.21) in quetia-
pine, −11.30 (0.70) in lithium, −9.43 (0.85) in paroxetine, 
and −7.85 (0.38) in placebo groups. In bipolar II patients, 
HAM-A score change was −10.84 (0.28), −9.62 (0.97), 
−8.65 (1.02), and −8.67 (0.47), respectively.
Bipolar I versus bipolar II subtype comparisons
Patients with bipolar II disorder consistently showed a 
slower response than bipolar I patients to all treatments, 
based on the week 4 assessments of mean MADRS, CGI-
S, and HAM-A scores. By week 8, however, the symptom 
improvements in bipolar II patients approximated those 
in bipolar I patients for each treatment (Figs.  5, 7, 8). 
Comparison of MADRS items showed broadly equivalent 
improvements in the bipolar I and II subtypes.
Safety assessments
An overview of adverse events and rates of the most fre-
quent adverse events (≥5 % of the safety population) in 
bipolar I or II patients are reported in Tables  5 and 6. 
Overall adverse event rates in the treatment groups were 
quetiapine (76.7 %, bipolar I; 74.5 %, bipolar II), lithium 
a
b
Fig. 3 Individual item scores for depression (a) and anxiety (b) at baseline in bipolar I and II subgroups (pooled population). HAM-A Hamilton rating 
scale for anxiety, MADRS Montgomery–Åsberg depression rating scale. HAM-A was not measured in Suppes et al. [25]. Rating scale ranges: HAM-A: 
total score range 0–56; MADRS: total score range 0–60. For all rating scales, a high score represents greater severity
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(54.0 %; 65.3 %), paroxetine (71.1 %; 66.7 %), and placebo 
(72.4 %; 66.5 %). Incidences of adverse events leading to 
discontinuation were, respectively, quetiapine (9.9  %; 
14.2  %), lithium (5.7  %; 10.2  %), paroxetine (11.8  %; 
4.4 %), and placebo (3.8 %; 4.1 %). Incidences of adverse 
events and of adverse events leading to discontinuation 
were broadly similar across the active treatment groups 
(Table 5). Adverse events were mild or moderate in inten-
sity in ≥80 % of both bipolar I and II patients in all treat-
ment groups with the exception of patients with bipolar I 
treated with paroxetine (66.7 %).
The profiles of adverse events reported in the pooled 
analyses are consistent with the known adverse event 
profiles of these agents, and as reported and discussed 
in the original papers [21–25]. Dry mouth, somnolence/
sedation, and dizziness were the most common adverse 
events above placebo rates in the quetiapine group; 
nausea, diarrhea, and tremor were common adverse 
events associated with lithium; and nausea and insomnia 
were common events in the paroxetine group.
There were no consistent differences in the incidence 
or profile of adverse events between patients with bipolar 
I and II disorder.
Weight change and changes in plasma glucose and lipid 
concentrations during treatment are reported in Table 7. 
Patients in the quetiapine group experienced a mean 
weight gain, while the metabolic parameters investigated 
showed no consistent differences between treatment 
groups or between patients with bipolar I and II disorder.
Discussion and conclusions
Bipolar II disorder has historically been perceived as 
less severe and disabling than bipolar I disorder. More 
recent reports suggest that the chronicity, frequency, 
a
b
Fig. 4 Patient-reported functioning and quality of life at baseline in bipolar I and II subgroups (pooled population). Q-LES-Q Quality of Life Enjoy-
ment and Satisfaction Questionnaire, SDS Sheehan Disability Scale. SDS was not measured in Calabrese et al. (2005) or Suppes et al. [25]. Q-LES-Q 
was not measured in Young et al. [28] or Suppes et al [25]. Rating scale ranges: Q-LES-Q: total score range 14–70; a high score represents greater 
enjoyment/satisfaction. SDS: total score range 0–30 (individual item score ranges: 0–10); a high score represents greater severity
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and duration of depressive episodes are typically greater 
in bipolar II than bipolar I disorder; while both disorder 
subtypes are equally disabling and impact quality of life 
outcomes. However, despite a similar prevalence and 
significant morbidity, the features and the treatment of 
bipolar II disorder have not been studied as extensively 
as the bipolar I subtype, providing limited evidence in the 
management of patients with bipolar II disorder.
This pooled analysis investigated baseline character-
istics in a large (n  =  2873) population of patients with 
bipolar I or II disorder enrolled in five acute treatment 
trials of quetiapine IR and XR in bipolar depression. In 
Fig. 5 Least squares mean change from baseline to week 8 in MADRS total score (ITT population, LOCF), BPI and BPII groups. Rating scale range: 
MADRS: total score range 0–60. A reduction in score represents improvement in depressive symptoms
Table 4 Least squares MADRS score change (mean, SE) during treatment in bipolar I and II subgroups (ITT population)
Analyses conducted using a linear mixed model (MMRM)
ITT intent-to-treat, MADRS Montgomery–Åsberg depression rating scale, NS nonsignificant





n Least squares MADRS  
score change (mean, SE)
Probabilitya n Least squares MADRS  
score change (mean, SE)
Probabilitya
Quetiapine
 Week 4 944 −15.01 (0.27) <.01 484 −13.96 (0.38) <.01
 Week 8 781 −19.01 (0.30) <.01 422 −18.44 (0.41) <.01
Lithium N = 87 N = 49
 Week 4 74 −11.16 (0.98) NS 41 −10.46 (1.31) NS
 Week 8 66 −17.71 (1.03) <.05 34 −17.46 (1.43) NS
Paroxetine n = 74 n = 44
 Week 4 59 −12.01 (1.09) NS 38 −13.38 (1.36) NS
 Week 8 45 −16.54 (1.24) NS 31 −15.35 (1.50) NS
Placebo n = 486 n = 231
 Week 4 388 −11.31 (0.43) – 198 −10.17 (0.60) –
 Week 8 304 −14.29 (0.48) – 164 −14.57 (0.65) –
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contrast to previous reports (e.g., Weinstock et al. [11]), 
the patients with bipolar II disorder enrolled in these 
studies had a generally similar burden of illness history as 
bipolar I disorder, while also confirming previous reports 
of similar baseline disability and impact on quality of life 
for both bipolar subtypes [1, 5, 6]. Since clinical features 
Fig. 6 Least squares mean change from baseline to week 8 in MADRS individual item scores (ITT population, LOCF), BPI and BPII groups. Rating 
scale range: MADRS: all item scores range 0–6. A reduction in score represents improvement in depressive symptoms. MADRS items: (1) apparent 
sadness; (2) reported sadness; (3) inner tension; (4) reduced sleep; (5) reduced appetite; (6) concentration difficulties; (7) lassitude; (8) inability to feel; 
(9) pessimistic thoughts; (10) suicidal thoughts
Fig. 7 Least squares mean change from baseline to week 8 in CGI-BP-S score (ITT population, LOCF), BPI and BPII groups. Rating scale range: CGI-S: 
total score range 0–7. A reduction in score represents improvement in overall severity of symptoms
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at the time of depressive episodes may not differentiate 
these two disorders or MDD, these findings suggest care-
ful inquiry into the chronicity of depressive episodes and 
of episodes suspicious for mania or hypomania can be 
important to establish an accurate diagnosis.
Changes in the severity of depression, anxiety, and 
overall burden of illness during 8  weeks of treatment 
in the five pooled, randomized clinical trials reported 
in this paper indicate that quetiapine provided earlier 
and greater symptom improvements than lithium or 
paroxetine. Interestingly, patients with bipolar II typi-
cally responded more slowly to treatments than patients 
with bipolar I, but by 8  weeks the symptom improve-
ments were similar in the two bipolar subgroups. Lith-
ium treatment also showed an initial delay in symptom 
improvement for both bipolar subtypes, but by 8 weeks 
approached a similar symptom improvement to que-
tiapine treatment. Conversely, paroxetine treatment 
initially followed symptom improvement similar to que-
tiapine; however, by 8  weeks improvement slowed and 
was similar to placebo. Statistical comparisons versus 
placebo indicated that quetiapine alone provided signif-
icant benefit at both 4 and 8 weeks and in both bipolar I 
and II populations.
Fig. 8 Least squares mean change from baseline to week 8 in HAM-A score (ITT population, LOCF), BPI and BPII groups. Rating scale range: HAM-A: 
total score range 0–56. A reduction in score represents improvement in anxiety symptoms
Table 5 Overview of adverse events (safety population)
Summary tables for AEs include those reported between the first dose and 30 days final dose of study medication
AE adverse event, BP bipolar, SAE serious AE
a Patients with multiple events in the same category are counted only once in that category
b Any AE that led to dose of treatment being changed or temporarily stopped, or deemed by the sponsor to be significant, excluding AEs reported as SAEs or led to 
discontinuation of treatment

















Any AE, n (%) 933 (76.7) 471 (74.5) 362 (72.4) 161 (66.5) 47 (54.0) 32 (65.3) 54 (71.1) 30 (66.7)
Any AE leading to discontinuation of treatment, n (%) 120 (9.9) 90 (14.2) 19 (3.8) 10 (4.1) 5 (5.7) 5 (10.2) 9 (11.8) 2 (4.4)
Any SAE (including outcome of death), n (%) 46 (3.8) 8 (1.3) 24 (4.8) 2 (0.8) 2 (2.3) 1 (2.0) 8 (10.5) 1 (2.2)
Any SAE leading to discontinuation of treatment, n (%) 30 (2.5) 4 (0.6) 13 (2.6) 1 (0.4) 2 (2.3) 0 (0.0) 5 (6.6) 0 (0.0)
Any other significant AEb, n (%) 17 (1.4) 12 (1.9) 5 (1.0) 1 (0.4) 3 (3.4) 0 (0.0) 1 (1.3) 1 (2.2)
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Descriptive assessments of the safety profile of the medi-
cations revealed no new findings relative to the original 
publications, with broadly similar incidences of adverse 
events and of adverse events leading to discontinuation for 
all active treatments in both bipolar I and II populations.
Limitations of these pooled analyses include their post-
hoc nature, the generalizability of the outcomes in the 
context of the studies’ selection criteria that excluded sig-
nificant comorbidities, and the acute duration of the five 
studies. We are, however, aware of no similar analyses in 
the literature that have compared baseline characteris-
tics and treatment response in bipolar II versus bipolar I 
patients by a pooled analysis of clinical trial data.
The observations made here, of a potentially slower 
response by bipolar II patients in all treatment arms, 
should inform prescribers and patients on expectations 
for improvement and when to consider changes in treat-
ment regimen versus longer watchful waiting.
Table 6 Adverse events occurring in greater than or equal to 5 % of patients in any group by preferred term in decreas-
ing frequency (safety population)

















Patients with events, n (%) 933 (76.7) 471 (74.5) 362 (72.4) 161 (66.5) 47 (54.0) 32 (65.3) 54 (71.1) 30 (66.7)
 Dry mouth 351 (28.8) 198 (31.3) 40 (8.0) 23 (9.5) 4 (4.6) 6 (12.2) 7 (9.2) 5 (11.1)
 Somnolence 287 (23.6) 130 (20.6) 28 (5.6) 18 (7.4) 5 (5.7) 7 (14.3) 1 (1.3) 6 (13.3)
 Sedation 216 (17.7) 128 (20.3) 32 (6.4) 14 (5.8) 1 (1.1) 0 (0.0) 6 (7.9) 4 (8.9)
 Dizziness 163 (13.4) 94 (14.9) 39 (7.8) 14 (5.8) 4 (4.6) 2 (4.1) 6 (7.9) 2 (4.4)
 Headache 107 (8.8) 65 (10.3) 69 (13.8) 43 (17.8) 8 (9.2) 5 (10.2) 12 (15.8) 7 (15.6)
 Constipation 103 (8.5) 49 (7.8) 16 (3.2) 11 (4.5) 2 (2.3) 2 (4.1) 6 (7.9) 0 (0.0)
 Nausea 85 (7.0) 47 (7.4) 50 (10.0) 22 (9.1) 10 (11.5) 13 (26.5) 7 (9.2) 8 (17.8)
 Fatigue 75 (6.2) 58 (9.2) 22 (4.4) 14 (5.8) 1 (1.1) 1 (2.0) 1 (1.3) 3 (6.7)
 Dyspepsia 51 (4.2) 33 (5.2) 14 (2.8) 6 (2.5) 3 (3.4) 1 (2.0) 2 (2.6) 0 (0.0)
 Upper respiratory tract infection 41 (3.4) 15 (2.4) 29 (5.8) 12 (5.0) 2 (2.3) 0 (0.0) 2 (2.6) 0 (0.0)
 Diarrhea 39 (3.2) 21 (3.3) 24 (4.8) 19 (7.9) 2 (2.3) 7 (14.3) 6 (7.9) 2 (4.4)
 Insomnia 34 (2.8) 10 (1.6) 33 (6.6) 15 (6.2) 8 (9.2) 4 (8.2) 8 (10.5) 8 (17.8)
 Tremor 26 (2.1) 16 (2.5) 4 (0.8) 2 (0.8) 3 (3.4) 5 (10.2) 2 (2.6) 1 (2.2)
 Pollakiuria 16 (1.3) 3 (0.5) 9 (1.8) 2 (0.8) 2 (2.3) 4 (8.2) 0 (0.0) 1 (2.2)
 Asthenia 14 (1.2) 13 (2.1) 1 (0.2) 4 (1.7) 0 (0.0) 5 (10.2) 2 (2.6) 0 (0.0)
 Decreased appetite 15 (1.2) 6 (0.9) 3 (0.6) 5 (2.1) 0 (0.0) 0 (0.0) 4 (5.3) 2 (4.4)
 Influenza 15 (1.2) 17 (2.7) 9 (1.8) 6 (2.5) 2 (2.3) 1 (2.0) 0 (0.0) 3 (6.7)
 Anxiety 13 (1.1) 17 (2.7) 13 (2.6) 10 (4.1) 4 (4.6) 1 (2.0) 3 (3.9) 3 (6.7)
Table 7 Weight, plasma glucose, and lipid data (safety population)

















Mean weight change (kg) 1.1 (4.8) 1.3 (5.5) −0.0 (2.5) 0.1 (2.4) 0.1 (2.1) 0.3 (2.2) −0.4 (3.2) −0.0 (1.9)
Weight change ≥ 7 %, n (%) 85 (7.0) 44 (7.0) 11 (2.2) 5 (2.1) 2 (2.3) 1 (2.0) 2 (2.6) 1 (2.2)
Glucose (mg/dL) 4.6 (21.5) 3.0 (14.4) 4.0 (20.3) 2.4 (14.6) 2.2 (18.9) 2.8 (11.8) 3.3 (13.2) −1.9 (15.3)
Insulin (pm/L) 49.9 (192.7) 27.9 (111.1) 15.6 (142.3) 19.1 (112.6) 6.0 (120.1) −18.3 (101.2) 14.5 (83.9) 15.0 (100.4)
Total cholesterol (mg/dL) −1.8 (31.9) −0.9 (31.6) −3.3 (27.6) −4.9 (31.2) −3.0 (37.9) −9.3 (31.5) −4.7 (37.9) 0.3 (30.9)
LDL-cholesterol (mg/dL) −3.1 (28.2) −2.8 (26.5) −3.2 (24.3) −5.1 (23.5) −3.9 (32.6) −6.8 (28.0) −5.9 (32.8) −3.3 (27.7)
HDL-cholesterol (mg/dL) −0.9 (9.4) −1.0 (9.3) 0.2 (8.8) −1.3 (8.9) −0.9 (13.3) 0.0 (8.9) 0.6 (12.4) 1.1 (10.2)
Triglycerides (mg/dL) 18.6 (112.8) 16.9 (85.1) −1.1 (111.8) 8.7 (112.2) 2.8 (81.1) −0.9 (62. 6) −5.0 (106.8) 26.9 (91.5)
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